General Information of Drug Therapeutic Target (DTT) (ID: TT6KSF7)

DTT Name Hepatitis B virus Large envelope protein (HBV S)
Synonyms Major surface antigen; Large surface protein; Large envelope protein; Large S protein; LHB; L-HBsAg; L glycoprotein
Gene Name HBV S
DTT Type
Clinical trial target
[1]
BioChemical Class
Orthohepadnavirus major surface antigen
UniProt ID
HBSAG_HBVA3
TTD ID
T53640
Sequence
MGGWSSKPRKGMGTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPVKDDWPAANQVGV
GAFGPRLTPPHGGILGWSPQAQGILTTVSTIPPPASTNRQSGRQPTPISPPLRDSHPQAM
QWNSTAFHQTLQDPRVRGLYLPAGGSSSGTVNPAPNIASHISSISARTGDPVTNMENITS
GFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGSPVCLGQNSQSPTSNHSPTSCP
PICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPCKTCTT
PAQGNSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGL
SPTVWLSAIWMMWYWGPSLYSIVSPFIPLLPIFFCLWVYI
Function
The large envelope protein exists in two topological conformations, one which is termed 'external' or Le-HBsAg and the other 'internal' or Li-HBsAg. In its external conformation the protein attaches the virus to cell receptors and thereby initiating infection. This interaction determines the species specificity and liver tropism. This attachment induces virion internalization predominantly through caveolin-mediated endocytosis. The large envelope protein also assures fusion between virion membrane and endosomal membrane. In its internal conformation the protein plays a role in virion morphogenesis and mediates the contact with the nucleocapsid like a matrix protein.

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nabi-HB DMHJVOL Hepatitis B virus infection 1E51.0 Approved [2]
------------------------------------------------------------------------------------
1 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
NASVAC DMIC56X Hepatitis B virus infection 1E51.0 Phase 3 [1]
------------------------------------------------------------------------------------

References

1 In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol. 2015 Feb;63(2):320-7.
2 Hepatitis B Immune Globulin (Human) Nabi-HB . US Food and Drug Administration report.